Biogen Idec grants Sunesis global rights to BTK inhibitor
To expand its hematology business, cancer-focused Sunesis Pharmaceuticals Inc. received exclusive worldwide rights to Biogen Idec Inc.’s preclinical Bruton's tyrosine kinase (BTK) inhibitor SNS062.
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com